Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to ...

Direct KRAS effector pathways involved in cell transformation & lung tumorigenesis RAF, PI3K and the RAL guanine exchange factor (RAL-GEF) were initially identified as essential components of RAS ...

Together, these studies uncover novel compensatory pathways that may be involved in tumor adaptation to inhibition of the KRAS–RAF–MEK–ERK pathway.

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U ...

The team demonstrated that tumor cells make new fat through the KRAS-MAPK pathway. "KRAS is the master regulator of pancreatic cancer, and new medicines are now in clinical trials to bring down ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Quiver AI Summary ...

Direct KRAS Effector Pathways Involved in Cell Transformation & Lung Tumorigenesis . KRAS activates signaling downstream of the RAF, PI3K and RAL pathways, which have been firmly established as ...